Our latest news
All News
Research
Network News
bioRN News
January 16, 2026
ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics
HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]
read more
January 16, 2026
AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million. The acquisition adds to Amgen’s […]
read more
January 16, 2026
Merger of the Heidelberg and Mannheim University Hospitals Launched
Science Minister Olschowski: A medical flagship model that will raise teaching, research and care to a new level of quality A medical flagship model that will raise teaching, research and care to a new level of quality and will be widely noted internationally: With these words, Petra Olschowski, Baden-Württemberg’s science minister, expressed appreciation of the […]
read more
January 16, 2026
Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis for cardiac amyloidosis / PET tracer AT-01 in Phase III and SPECT tracer AT-05 in Phase I of clinical development specifically designed for the diagnosis of cardiac as well as other types of systemic amyloidosis […]
read more
January 16, 2026
BioMed X Launches XBridge Pilot to Facilitate Industry-Academic Research Collaborations
Heidelberg, Germany, January 13, 2026 – BioMed X announced today the launch of a pilot initiative with Harvard University under BioMed X’s XBridge framework to support structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements. The XBridge pilot is designed to connect senior biomedical researchers and principal investigators at Harvard with researchers from pharmaceutical companies seeking to […]
read more
January 16, 2026
Predicting the Ever-Changing World of Protein Dynamics
In July 2025, a team of researchers from HITS and the Max Planck Institute for Polymer Research (MPIP) developed a model that learns how to generate proteins with highly flexible structures. A new, complementary deep learning model — Back Bone Flow (BBFlow) — can now predict the dynamics of proteins, providing insights into how they function. Their […]
read more
January 16, 2026
BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026 FRANKLIN LAKES, N.J., Jan. 15, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal […]
read more
January 15, 2026
life – the biomedical convention – 30 Jahre bioRN Life Science Cluster: Impulsgeber für die nächste Generation biomedizinischer Innovation
Heidelberg, 15. Januar 2026 – Am 4. Februar 2026 lädt der bioRN Life Science Cluster zur life – the biomedical convention in das Heidelberg Congress Center ein. Die internationale Fachkonferenz bringt Wissenschaft, Industrie, Startups und Innovationsakteure zusammen und zeigt, warum der bioRN Life Science Cluster zu den leistungsfähigsten Life-Science-Ökosystemen Europas zählt. Im Zentrum der eintägigen […]
read more
January 11, 2026
Ikarovec to advance pipeline with exclusive worldwide option to VectorBuilder’s Intravitreal Capsid Technology
Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease NORWICH, UK & CHICAGO, US, January 6 2026 – Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive […]
read more
